Related Experiment Video
Updated: Jun 17, 2025
Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
Published on: January 20, 2023
Soluble ST2 Is a Biomarker Associated With Left Ventricular Hypertrophy and Concentric Hypertrophy in Patients With
Xia Wang1,2, Shu-Jie Han1,2, Xiao-Li Wang1,2
1Department of Cardiovascular, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Insights
Elevated soluble stimulating factor 2 (sST2) levels are linked to left ventricular hypertrophy (LVH) and concentric hypertrophy (CH) in essential hypertension (EH). This biomarker can aid in diagnosing and assessing the risk of hypertensive heart disease.
Area of Science:
- Cardiology
- Biomarkers
- Hypertension Research
Background:
- Elevated soluble stimulating factor 2 (sST2) is associated with cardiovascular diseases, reflecting myocardial fibrosis and hypertrophy.
- The role of sST2 in hypertensive heart disease, specifically left ventricular hypertrophy (LVH) and geometric remodeling, remains less understood.
- Essential hypertension (EH) is a significant risk factor for cardiovascular complications.
Purpose of the Study:
- To investigate the relationship between sST2 levels and left ventricular hypertrophy (LVH) in patients with essential hypertension (EH).
- To determine the association of sST2 with left ventricular geometric remodeling in EH.
- To evaluate sST2 as a potential biomarker for hypertensive heart disease.
Main Methods:
- A cohort of 483 patients with essential hypertension (aged 18-80 years) was enrolled.
- Serum sST2 levels were measured.
- Echocardiographic analyses were performed to assess left ventricular mass, mass index, LVH, and geometric remodeling.
Main Results:
- Stepwise multiple linear regression revealed significant associations between sST2, left ventricular (LV) mass, and LV mass index.
- The prevalence of LVH and concentric hypertrophy (CH) increased with higher sST2 levels (P for trend < 0.05).
- Logistic regression showed the highest tertile of sST2 was significantly associated with increased LVH (OR: 6.61) and CH (OR: 5.80) risk. ROC analysis indicated sST2's predictive value for LVH and CH (AUC ~0.752).
Conclusions:
- High sST2 levels are strongly correlated with LVH and CH in patients with EH.
- sST2 demonstrates potential as a diagnostic and risk assessment biomarker for hypertensive heart disease.
- These findings highlight the clinical utility of sST2 in managing patients with essential hypertension and associated cardiac conditions.
Background:
Elevated soluble stimulating factor 2 (sST2) level is observed in cardiovascular diseases, such as heart failure and acute coronary syndrome, which reflects myocardial fibrosis and hypertrophy, indicating adverse clinical outcomes. However, the association between sST2 and hypertensive heart disease are less understood. This study aimed to determine the relationship of sST2 with left ventricular hypertrophy (LVH) and geometric remodeling in essential hypertension (EH).
Methods:
We enrolled 483 patients (aged 18-80 years; 51.35% female). sST2 measurements and echocardiographic analyses were performed.
Results:
Stepwise multiple linear regression analysis showed significant associations among sST2, left ventricular (LV) mass, and LV mass index. The prevalence of LVH and concentric hypertrophy (CH) increased with higher sST2 grade levels (P for trend < 0.05). Logistic regression analysis suggested that the highest tertile of sST2 was significantly associated with increased LVH risk, compared with the lowest tertile (multivariate-adjusted odds ratio [OR] of highest group: 6.61; P < 0.001). Similar results were observed in the left ventricular geometric remodeling; the highest tertile of sST2 was significantly associated with increased CH risk (multivariate-adjusted OR of highest group: 5.80; P < 0.001). The receiver operating characteristic analysis results revealed that sST2 had potential predictive value for LVH (area under the curve [AUC]: 0.752, 95% confidence interval [CI]: 0.704-0.800) and CH (AUC: 0.750, 95% CI: 0.699-0.802) in patients with EH.
Conclusions:
High sST2 level is strongly related to LVH and CH in patients with EH and can be used as a biomarker for the diagnosis and risk assessment of hypertensive heart disease.
Clinical Trials Registration:
Trial Number ChiCTR2400082764.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...